Monitor for updates from the FDA meeting and any subsequent resubmission plans. The rejection removes a key pipeline catalyst for NVCR, and the stock may re-rate lower until a clear path to approval emerges.
Drug in focus
NVCR drug pipeline →Optune Mya
▼ Bearish Named in this 8-K- Impact
- Phase
- Filed/PMA (Not Approvable Letter received)
- Time to market
- Uncertain; the FDA rejected the current PMA application. NovoCure plans to meet with the FDA to discuss options that may not require additional clinical studies, but no timeline for a resubmission or potential approval has been established.
- Next catalyst
- None dated
What to watchThe FDA's Not Approvable Letter for Optune Mya removes a key pipeline catalyst. Watch for NovoCure's planned meeting with the FDA to see if a path forward emerges without additional clinical studies. Separately, the Dec 31, 2026 PDUFA for Optune Pax (a different device) in the same brain metastases indication remains a major upcoming binary for NVCR.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $12.53entry
- T+1 · 7d ago −5.75%α −5.38% · $11.81
- T+5 · 16h ago −9.82%α −8.12% · $11.30
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NovoCure received a Not Approvable Letter from the FDA for its PMA application for Optune Mya to treat brain metastases from non-small cell lung cancer. The FDA cited uncertainty around clinical benefit but raised no safety concerns. The company plans to meet with the FDA to explore options that would not require additional clinical studies, but there is no assurance of eventual approval.
Key Facts
- FDA issued a Not Approvable Letter for Optune Mya PMA for brain metastases from non-small cell lung cancer
- FDA determined uncertainty around the degree of clinical benefit prevented approval
- FDA did not raise concerns related to the safety profile of Optune Mya
- NovoCure plans to meet with the FDA to explore options that would not require additional clinical studies
- No assurance that discussions or future submissions will lead to approval
Financial Impact
Loss of a potential new product approval for a $1.6B market cap company; no financial figures provided in the filing
Risk Factors
- Additional clinical studies may be required, delaying or preventing approval
- No guarantee of eventual FDA approval for this indication
- Potential negative impact on investor sentiment and stock price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001645113-26-000085 |
| Document: myadecisionpr.htm | 0001645113-26-000085 |
| Document: 0001645113-26-000085-index-headers.html | 0001645113-26-000085 |
| Document: 0001645113-26-000085-index.html | 0001645113-26-000085 |
| Document: 0001645113-26-000085.txt | 0001645113-26-000085 |
Track record
20 reports on NVCR
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Viewing Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
- Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
- Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers